drugset / Trial / NCT02052609
A Phase 3 Clinical Study of KHK 4827
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).
Timeline
- Start
- 2014-02
- Primary completion
- 2015-01-28
- Completion
- 2016-07-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brodalumab | Monoclonal antibody | 140 mg | Subcutaneous |
| Subject | Brodalumab | Monoclonal antibody | 210 mg | Subcutaneous |